First-Line Nivolumab plus Ipilimumab Shows Activity in MSI ...
Nivolumab and low-dose ipilimumab show durable clinical benefit for MSI-H/dMMR metastatic CRC patients, with 74% PFS and 79% OS rates at 24 months. The combination, effective in first-line and previously treated patients, is well-tolerated, offering a new treatment option.
Reference News
First-Line Nivolumab plus Ipilimumab Shows Activity in MSI ...
Nivolumab and low-dose ipilimumab show durable clinical benefit for MSI-H/dMMR metastatic CRC patients, with 74% PFS and 79% OS rates at 24 months. The combination, effective in first-line and previously treated patients, is well-tolerated, offering a new treatment option.